

ORGENTEC Diagnostika GmbH


Carl-Zeiss-Straße 49-51

55129 Mainz - Germany

Phone: +49 (0) 61 31 / 92 58-0

Fax: +49 (0) 61 31 / 92 58-58

Internet: www.orgentec.com



ORG 548 Anti-MCV

INTENDED PURPOSE

Anti-MCV is an ELISA test system for the quantitative measurement of IgG class autoantibodies against mutated citrullinated vimentin (MCV) in human serum or plasma. This product is intended for professional in vitro diagnostic use only.

Measurement of anti-MCV antibodies contributes to early diagnosis of rheumatoid arthritis (RA), where anti-MCV antibody levels represent one parameter of a multi-criterion diagnostic process, encompassing both clinical and laboratory-based assessments.

SYMBOLS USED ON LABELS

	In vitro diagnostic medical device		Microplate
	Manufacturer		Calibrator
	Catalogue number		Calibrator
	Sufficient for 96 determinations		Calibrator
	Batch code		Calibrator
	Use by		Calibrator
	Temperature limitation		Calibrator
	Keep away from sunlight		Control positive
	Do not reuse		Control negative
	Date of manufacture		Sample Buffer P
	CE marked according to 98/79/EC		Enzyme Conjugate
	Consult instructions for use		TMB Substrate
	Electronic Instruction For Use: version		Stop solution
			Wash Buffer
			Ready to use

PRINCIPLE OF THE TEST

Mutated citrullinated vimentin (MCV) is bound to microwells.

The determination is based on an indirect enzyme linked immune reaction with the following steps:

Specific antibodies in the patient sample bind to the antigen coated on the surface of the reaction wells. After incubation, a washing step removes unbound and unspecifically bound serum or plasma components. Subsequently added enzyme conjugate binds to the immobilized antibody-antigen-complexes. After incubation, a second washing step removes unbound enzyme conjugate. After addition of substrate solution the bound enzyme conjugate hydrolyses the substrate forming a blue coloured product. Addition of an acid stops the reaction generating a yellow end-product. The intensity of the yellow color correlates with the concentration of the antibody-antigen-complex and can be measured photometrically at 450 nm.

WARNINGS AND PRECAUTIONS

- All reagents of this kit are intended for professional in vitro diagnostic use only.
- Components containing human serum were tested and found negative for HBsAg, HCV, HIV1 and HIV2 by FDA approved methods. No test can guarantee the absence of HBsAg, HCV, HIV1 or HIV2, and so all human serum based reagents in this kit must be handled as though capable of transmitting infection.
- Bovine serum albumin (BSA) used in components has been tested for BSE and found negative.
- Avoid contact with the substrate TMB (3,3',5,5'-Tetramethyl-benzidine).
- Stop solution contains acid, classification is non-hazardous. Avoid contact with skin.
- Control, sample buffer and wash buffer contain sodium azide 0.09% as preservative. This concentration is classified as non-hazardous.
- Enzyme conjugate contains ProClin 300 0.05% as preservative. This concentration is classified as non-hazardous.

During handling of all reagents, controls and serum samples observe the existing regulations for laboratory safety regulations and good laboratory practice:

- First aid measures: In case of skin contact, immediately wash thoroughly with water and soap. Remove contaminated clothing and shoes and wash before reuse. If system fluid comes into contact with skin, wash thoroughly with water. After contact with the eyes carefully rinse the opened eye with running water for at least 10 minutes. Get medical attention if necessary.
 - Personal precautions, protective equipment and emergency procedures:
Observe laboratory safety regulations. Avoid contact with skin and eyes. Do not swallow. Do not pipette by mouth. Do not eat, drink, smoke or apply makeup in areas where specimens or kit reagents are handled. When spilled, absorb with an inert material and put the spilled material in an appropriate waste disposal.
 - Exposure controls / personal protection: Wear protective gloves of nitril rubber or natural latex. Wear protective glasses. Used according to intended use no dangerous reactions known.
 - Conditions to avoid: Since substrate solution is light-sensitive. Store in the dark.
 - For disposal of laboratory waste the national or regional legislation has to be observed.
- Observe the guidelines for performing quality control in medical laboratories by assaying control sera.

CONTENTS OF THE KIT

ORG 548	▽ 96	Sufficient for 96 determinations
MICROPLATE	1	One divisible microplate consisting of 12 modules of 8 wells each. Ready to use. Product code on module: MCV
CALIBRATOR A	1x 1.5 ml	Calibrator A 0 U/ml, containing serum/buffer matrix (PBS, BSA, detergent, NaN3 0.09%), yellow. Ready to use.
CALIBRATOR B	1x 1.5 ml	Calibrator B 20 U/ml, containing MCV antibodies in a serum/buffer matrix (PBS, BSA, detergent, NaN3 0.09%), yellow. Ready to use.
CALIBRATOR C	1x 1.5 ml	Calibrator C 40 U/ml, containing MCV antibodies in a serum/buffer matrix (PBS, BSA, detergent, NaN3 0.09%), yellow. Ready to use.
CALIBRATOR D	1x 1.5 ml	Calibrator D 100 U/ml, containing MCV antibodies in a serum/buffer matrix (PBS, BSA, detergent, NaN3 0.09%), yellow. Ready to use.
CALIBRATOR E	1x 1.5 ml	Calibrator E 300 U/ml, containing MCV antibodies in a serum/buffer matrix (PBS, BSA, NaN3 0.09%), yellow. Ready to use.
CALIBRATOR F	1x 1.5 ml	Calibrator F 1000 U/ml, containing MCV antibodies in a serum/buffer matrix (PBS, BSA, detergent, NaN3 0.09%), yellow. Ready to use.
CONTROL +	1x 1.5 ml	Control positive, containing MCV antibodies in a serum/buffer matrix (PBS, BSA, detergent, NaN3 0.09%), yellow. Ready to use. The concentration is specified on the certificate of analysis.
CONTROL -	1x 1.5 ml	Control negative, containing MCV antibodies in a serum/buffer matrix (PBS, BSA, detergent, NaN3 0.09%), yellow. Ready to use. The concentration is specified on the certificate of analysis.
DILUENT	20 ml	Sample Buffer P, containing PBS, BSA, detergent, preservative sodium azide 0.09%, yellow, concentrate (5 x).
CONJUGATE	15 ml	Enzyme Conjugate containing anti-human IgG antibodies, HRP labelled; PBS, BSA, detergent, preservative PROCLIN 0.05%, light red. Ready to use.
TMB	15 ml	TMB Substrate; containing 3,3', 5,5'- Tetramethylbenzidin, colorless. Ready to use.
STOP	15 ml	Stop solution; contains acid. Ready to use.
WASH	20 ml	Wash Buffer, containing Tris, detergent, preservative sodium azide 0.09%; 50 x conc.
i	1	Certificate of Analysis

MATERIALS REQUIRED

- Microplate reader capable of endpoint measurements at 450 nm; optional: reference filter at 620 nm
- Data reduction software
- Multi-channel dispenser or repeatable pipette for 100 µl
- Vortex mixer
- Pipettes for 10 µl, 100 µl and 1000 µl
- Laboratory timing device
- Distilled or deionised water
- Measuring cylinder for 1000 ml and 100 ml
- Plastic container for storage of the wash solution

This ELISA assay is suitable for use on open automated ELISA processors. Each assay has to be validated on the respective automated system. Detailed information is provided upon request.

SPECIMEN COLLECTION, STORAGE AND HANDLING

- Collect whole blood specimens using acceptable medical techniques to avoid hemolysis.
- Allow blood to clot and separate the serum or plasma by centrifugation.
- Test serum should be clear and non-hemolyzed. Contamination by hemolysis or lipemia should be avoided, but does not interfere with this assay.
- Specimens may be refrigerated at 2-8°C for up to five days or stored at -20°C up to six months.
- Avoid repetitive freezing and thawing of serum or plasma samples. This may result in variable loss of antibody activity.
- Testing of heat-inactivated sera is not recommended.

STORAGE AND STABILITY

- Store test kit at 2-8°C in the dark.
- Do not expose reagents to heat, sun, or strong light during storage and usage.
- Store microplate sealed and dessicated in the clip bag provided.
- Shelf life of the unopened test kit is 18 months from day of production.
Unopened reagents are stable until expiration of the kit. See labels for individual batch.
- Diluted Wash Buffer and Sample Buffer are stable for at least 30 days when stored at 2-8°C.
We recommend consumption on the same day.

PROCEDURAL NOTES

- Do not use kit components beyond their expiration dates.
- Do not interchange kit components from different lots and products.
- All materials must be at room temperature (20-28°C) prior to use.
- Prepare all reagents and samples. Once started, perform the test without interruption.
- Double determinations may be done. By this means pipetting errors may become obvious.
- Perform the assay steps only in the order indicated.
- Always use fresh sample dilutions.
- Pipette all reagents and samples into the bottom of the wells.
- To avoid carryover or contamination, change the pipette tip between samples and different kit controls.
- Wash microwells thoroughly and remove the last droplets of wash buffer.
- All incubation steps must be accurately timed.
- Do not re-use microplate wells.

PREPARATION OF REAGENTS

WASH

Dilute the contents of one vial of the buffered wash solution concentrate (50x) with distilled or deionised water to a final volume of 1000 ml prior to use.

DILUENT

Sample Buffer P: Prior to use dilute the contents (20 ml) of one vial of sample buffer 5x concentrate with distilled or deionised water to a final volume of 100 ml.

Preparation of samples

Dilute patient samples 1:100 before the assay: Put 990 µl of prediluted sample buffer in a polystyrene tube and add 10 µl of sample. Mix well. Note: Calibrators / Controls are ready to use and need not be diluted.

TEST PROCEDURE

Prepare enough microplate modules for all calibrators / controls and patient samples.

- Pipette **100 µl** of calibrators, controls and prediluted patient samples into the wells.
Incubate for **30 minutes** at room temperature (20-28 °C).
Discard the contents of the microwells and **wash 3 times** with **300 µl** of wash solution.
- Dispense **100 µl** of enzyme conjugate into each well.
Incubate for **15 minutes** at room temperature.
Discard the contents of the microwells and **wash 3 times** with **300 µl** of wash solution.
- Dispense **100 µl** of TMB substrate solution into each well.
Incubate for **15 minutes** at room temperature
- Add 100 µl** of stop solution to each well of the modules
Incubate for **5 minutes** at room temperature.
Read the optical density at 450 nm (reference 600-690nm) and calculate the results.
The developed colour is stable for at least 30 minutes. Read during this time.

Example for a pipetting scheme:

	1	2	3	4	5	6	7	8	9	10	11	12
A	A	P1										
B	B	P2										
C	C	P3										
D	D											
E	E											
F	F											
G	C+											
H	C-											

P1, ... patient sample A-F calibrators C+, C- controls

VALIDATION

Test results are valid if the optical densities at 450 nm for calibrators / controls and the results for controls comply with the reference ranges indicated on the Certificate of Analysis enclosed in each test kit.
If these quality control criteria are not met the assay run is invalid and should be repeated.

CALCULATION OF RESULTS

For quantitative results plot the optical density of each calibrator versus the calibrator concentration to create a calibration curve. The concentration of patient samples may then be estimated from the calibration curve by interpolation.

Using data reduction software a 4-Parameter-Fit with lin-log coordinates for optical density and concentration is the data reduction method of choice.

PERFORMANCE CHARACTERISTICS

CALIBRATION

This assay system is calibrated in relative arbitrary units, since no international reference preparation is available for this assay.

Measuring range

The calculation range of this ELISA assay is 0 - 1000 U/ml

Expected values

In a normal range study with samples from healthy blood donors the following ranges have been established with this ELISA assay: Cut-off 20 U/ml

Interpretation of results

Negative: < 20 U/ml
Positive: ≥ 20 U/ml

Linearity

Patient samples containing high levels of specific antibody were serially diluted in sample buffer to demonstrate the dynamic range of the assay and the upper / lower end of linearity. Activity for each dilution was calculated from the calibration curve using a 4-Parameter-Fit with lin-log coordinates.

Sample	Dilution	Observed U/ml	Expected U/ml	O/E [%]
1	1:100	882.8	882.8	100
.	1:200	386.0	441.4	87
.	1:400	205.2	220.7	93
.	1:800	110.7	110.4	100
.	1:1600	52.2	55.2	95
.	1:3200	23.4	27.6	85
2	1:100	932.1	932.1	100
.	1:200	486.0	466.1	104
.	1:400	250.1	233.0	107
.	1:800	126.6	116.5	109
.	1:1600	61.7	58.3	106
.	1:3200	28.2	29.1	97
3	1:100	727.9	727.9	100
.	1:200	362.4	364.0	100
.	1:400	178.2	182.0	98
.	1:800	85.7	91.0	94
.	1:1600	47.1	45.5	104
.	1:3200	19.2	22.7	85

Limit of detection

Functional sensitivity was determined to be: 1 U/ml

Reproducibility

Intra-assay precision: Coefficient of variation (CV) was calculated for each of three samples from the results of 24 determinations in a single run. Results for precision-within-assay are shown in the table below.

Inter-assay precision: Coefficient of variation (CV) was calculated for each of three samples from the results of 6 determinations in 5 different runs. Results for run-to-run precision are shown in the table below.

Intra-Assay		
Sample	Mean U/ml	CV %
1	22.7	6.2
2	118.8	6.4
3	548.1	4.6

Inter-Assay		
Sample	Mean U/ml	CV %
1	20.2	5.3
2	111.0	9.2
3	451.6	7.7

Interfering substances

No interference has been observed with haemolytic (up to 1000 mg/dl) or lipemic (up to 3 g/dl triglycerides) sera or plasma, or bilirubin (up to 40 mg/dl) containing sera or plasma. Nor have any interfering effects been observed with the use of anticoagulants (Citrate, EDTA, Heparine). However for practical reasons it is recommended that grossly hemolyzed or lipemic samples should be avoided.

Study results

Study population	n	n Pos	%
Rheumatoid arthritis	490	398	81.2
Other diseases	522	14	2.7
Normal human sera	234	1	0.4

		Clinical Diagnosis		
		POS	NEG	
ORG 548	POS	398	15	
	NEG	92	741	
		490	756	1246

Sensitivity: 81.2 %
Specificity: 98.0 %
Overall agreement: 91.4 %

LIMITATIONS OF THE PROCEDURE

This assay is a diagnostic aid. A definite clinical diagnosis should not be based on the results of a single test, but should be made by the physician after all clinical and laboratory findings have been evaluated concerning the entire clinical picture of the patient. Also every decision for therapy should be taken individually.

The above pathological and normal reference ranges for antibodies in patient samples should be regarded as recommendations only. Each laboratory should establish its own ranges according to ISO 15189 or other applicable laboratory guidelines.

REFERENCES

1. F.Bobbio-Pallavicini, C.Alpini, R.Caporali, S.Avale, S.Bugatti, C.Montecuccio. Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. *Arthritis Res Ther* 2004; 6:R264-R272 (DOI 10.1186/ar1173)
2. E.R.Vossenaar, N.Deprés, E.Lapointe, A. van der Heijden, M.Lora, T.Senshu, W.J. van Venrooij, H.A.Ménard. Rheumatoid arthritis specific anti Sa antibodies target citrullinated vimentin. *Arthritis Research & Therapie* Vol.6 No.2
3. O.Vittecoq, S.Poplin, K.Krzyszowska, F.Jouen-Beades, J.F.Ménard, A.Daragon, F.Tron, X.Loet. Rheumatoid Factor is the strongest predictor of radiological progression of rheumatoid arthritis in a three-year prospective study in community-recruited patients. *Rheumatology* 2003; 42:939-946
4. W.J. van Venrooij, J.M.Hazes, H.Visser. Anticitrullinated protein/peptide antibody and its role in the diagnosis and prognosis of early rheumatoid arthritis. *The Netherland Journal of Medicine*.
5. M.Escalon, F.J.Lópees-Longo, C.M. González, I.Monteagudo, M.Rodríguez-Mahou, R.Grau, L.Carreno. Anti-Sa Sera from patients with Rheumatoid Arthritis contain at least 2 different subpopulations of Anti-Sa antibodies. *The Journal of Rheumatology* 2002; 29:10 2053-60
6. Ch.Vincent, L.Nogueira, M.Sebba, S.Chapuy-Regaud, M.Arnaud, O.Letourneur, D.Rolland, B.Rounie, A. Cantagrel, M.Jolivet, G.Serre. Detecion of antibodies to determined recombinant tat flaggrin by Enzyme-Linked Immunosorbent Assay. *Arthritis & Rheumatism* Vo. 46, No.8, August 2002, pp. 2051 -58
7. G.Steiner, J.Smolen. Antibodies in rheumatoid arthritis and their clinical significance. *Arthritis Res* 2002,4 (suppl 2);S1-S5
8. R.Goldbach-Mansky, J.Lee, A.McCoy, J.Hoxworth, C.Yarboro, J.S.Smolen, G.Steiner, A.Rosen, C.Zhang, H.A. Ménard, Z.J.Zhou, T.Palosuo, W.J.Van Venrooij, R.L.Wilder, J.H.Klippel, H.R.Schumacher Jr., H.S.El-Gabalawy. Rheumatoid arthritis associated antibodies in patients with synovitis of recent onset. *Arthritis Res* 2000,2:236-243
9. H.Ménard, E.Lapointe, M.D.Rochdi, Z.J.Zhou. Insights into rheumatoid arthritis derived from the Sa immune system. *Arthritis Research* 2000,2:429-432
10. G.Hayem, P.Chazerain, B.Combe, A.Elias, T.Haim, P.Nicaise, K.Benali, J-F Eliau, M-F Kahn, J.Sany, O.Meyer. Anti-Sa antibody is an accurate diagnostic and prognostic Marker in adult Rheumatoid Arthritis. *The Journal of Rheumatology* 1999;26:7-13
11. N. Deprés, G.Boire, F.J.Lopez-Longo, H.A. Ménard. The Sa System : A novel antigen antibody system specific for rheumatoid arthritis. *The Journal of Rheumatology* 1994; 21 :1 027- 33
12. E.R.Vossenaar, T.R.D. Radstake, A. van der Heijden, M.A.M. van Mansum, C. Dieteren, D.-J. de Rooij, P. Barrera, A.J.W. Zendman, W.J. van Venrooij. Expression and activity of citrullinase peptidylarginine deiminase enzymes in monocytes and macrophages. *Ann Rheum Dis* 2004; 63:373-381
13. H. Burkhardt, B. Sehnert, R. Bockermann, A. Engström, J.R. Kalden, R. Holmdahl. Humoral immune response to citrullinated collagen type II determinants in early rheumatoid arthritis. *Eur. J. Immunol.* 2005.35: 1643-1652
14. Ch.Vincent, L. Nogueira, C. Clavel, M. Sebbag, G. Serre. Autoantibodies to citrullinated pro-teins: ACPA. *Autoimmunity*, February 2005; 38 (1): 17-24
15. M. Sebbag, S. Chapuy-Regaud, I. Auger, E. Petit-Teixeira, C. Clavel, L. Nogueira, Ch.Vincent, F. Cornélis, J. Roudier, G. Serre. Clinical and pathophysiological significance of the autoimmune response to citrullinated proteins in rheumatoid arthritis. *Joint bone Spine* 71 (2004) 493-502

References Concerning Classification of RA

16. Liao KP, Batra KL, Chibnik L, Schur PH, Costenbader KH. Anti-CCP revised criteria for the classification of rheumatoid arthritis. *Ann Rheum Dis* 2008.
17. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum* 1988; 31(3):315-24. Further Reading on Diagnostic Performance of Anti-MCV vs. Predicate Assay:
18. Gyetvai A, Szekanez Z, Soos L, Szabo Z, Fekete A, Kapitany A et al. New classification of the shared epitope in rheumatoid arthritis: impact on the production of various anti-citrullinated protein antibodies. *Rheumatology (Oxford)* 2010; 49(1):25-33.
19. Pruijn G, Wiik A, van Venrooij W. The use of citrullinated peptides and proteins for the diagnosis of rheumatoid arthritis. *Arthritis Research & Therapy* 2010; 12(1):203.
20. Aggarwal R, Liao K, Nair R, Ringold S, Costenbader KH. Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis. *Arthritis Rheum* 2009; 61(11):1472-83.
21. Feitsma AL, van der Voort EI, Franken KL, El BH, Elferink BG, Drijfhout JW et al. Identification of citrullinated vimentin peptides as T cell epitopes in HLA-DR4-positive patients with rheumatoid arthritis. *Arthritis Rheum* 2009; 62(1):117-25.
22. Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. *Lancet* 2009; 373(9664):659-72.
23. Liu X, Jia R, Zhao J, Li Z. The Role of Anti-Mutated Citrullinated Vimentin Antibodies in the Diagnosis of Early Rheumatoid Arthritis. *J Rheumatol* 2009.
24. Luime JJ, Colin EM, Hazes JM, Lubberts E. Does anti-MCV has additional value as serological marker in the diagnostic and prognostic work-up of patients with rheumatoid arthritis? A systematic review. *Ann Rheum Dis* 2009.
25. Mjaavatten MD, Uhlig T, Haugen AJ, Nygaard H, Sidenvall G, Helgetveit K et al. Positive anti-citrullinated protein antibody status and small joint arthritis are consistent predictors of chronic disease in patients with very early arthritis: results from the NOR-VEAC cohort. *Arthritis Res Ther* 2009; 11(5):R146.
26. Engelmann R, Brandt J, Eggert M, Karberg K, Krause A, Neeck G et al. The Anti-mutated Citrullinated Vimentin Response Classifies Patients with Rheumatoid Arthritis into Broad and Narrow Responders. *J Rheumatol* 2009.
27. Raza K, Mathsson L, Buckley CD, Filer A, Ronnelid J. Anti-modified citrullinated vimentin (MCV) antibodies in patients with very early synovitis. *Ann Rheum Dis* 2009.
28. Snir O, Widhe M, Hermansson M, von SC, Lindberg J, Hensen S et al. Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients. *Arthritis Rheum* 2009; 62(1):44-52.
29. Syversen SW, Goll GL, van der Heijde D, Landewe R, Lie BA, Odegard S et al. Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a ten-year prospective study. *Ann Rheum Dis* 2009.
30. van der Linden MP, van der Woude D, Ioan-Facsinay A, Levarht EW, Stoeken-Rijsbergen G, Huizinga TW et al. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. *Arthritis Rheum* 2009; 60(8):2232-41.
31. Wagner E, Skoumal M, Bayer PM, Klaushofer K. Antibody against mutated citrullinated vimentin: a new sensitive marker in the diagnosis of rheumatoid arthritis. *Rheumatol Int* 2009.
32. Keskin G, Inal A, Keskin D, Pekel A, Baysal O, Dizer U et al. Diagnostic Utility of Anti-Cyclic Citrullinated Peptide and Anti-Modified Citrullinated Vimentin Antibodies in Rheumatoid Arthritis. *Protein Pept Lett* 2008; 15 (3):314-7.
33. Szekanez Z, Lakos G. Rheumatoid arthritis diagnosis with antimutated citrullinated vimentin ELISA by Orgentec Diagnostika. *Exp Opin Med Diagnostics* 2008; 2(9):1083-90.
34. Szekanez Z, Soos L, Szabo Z, Fekete A, Kapitany A, Vegvari A et al. Anti-Citrullinated Protein Antibodies in Rheumatoid Arthritis: As Good as it Gets? *Clin Rev Allergy Immunol* 2008; 34(1):26-31.

Notice to the user (European Union):

Any serious incident that has occurred in relation to the device shall be reported to the manufacturer and the competent authority of the EU Member State in which the user and/or the patient is established .

Change Control

Former version: *ORG 548_IFU_EN_QM113183_2013-12-16_1.2* Reason for revision: *Introduction electronic IFU on homepage*

- 1 Pipet **100 µl** calibrator, control or patient sample
 - Incubate for **30 minutes** at room temperature
 - Discard the contents of the wells and wash 3 times with **300 µl** wash solution
- 2 Pipet **100 µl** enzyme conjugate
 - Incubate for **15 minutes** at room temperature
 - Discard the contents of the wells and wash 3 times with **300 µl** wash solution
- 3 Pipet **100 µl** substrate solution
 - Incubate for **15 minutes** at room temperature
- 4 Add **100 µl** stop solution
 - Leave untouched for **5 minutes**
 - Read at **450 nm**